Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CV Sciences (CVSI) EBITDA Margin (2016 - 2025)

CV Sciences' EBITDA Margin history spans 13 years, with the latest figure at 8.45% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 38.0% year-over-year to 8.45%; the TTM value through Sep 2025 reached 4.48%, up 2006.0%, while the annual FY2024 figure was 3.22%, 2421.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 8.45% at CV Sciences, down from 3.62% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 138.91% in Q1 2023 and bottomed at 177.96% in Q4 2021.
  • The 5-year median for EBITDA Margin is 23.39% (2023), against an average of 25.48%.
  • The largest annual shift saw EBITDA Margin skyrocketed 17298bps in 2023 before it plummeted -15440bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 177.96% in 2021, then soared by 69bps to 54.92% in 2022, then surged by 57bps to 23.39% in 2023, then skyrocketed by 214bps to 26.75% in 2024, then plummeted by -132bps to 8.45% in 2025.
  • Per Business Quant, the three most recent readings for CVSI's EBITDA Margin are 8.45% (Q3 2025), 3.62% (Q2 2025), and 0.31% (Q1 2025).